Bio-Rad Laboratories manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The company was founded in 1952 and is based in Hercules, California.
BIO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for BIO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bio-Rad Laboratories Inc ranked in the 33th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Bio-Rad Laboratories Inc, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 196.01 -- which is good for besting 97.7% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 14% of the free cash flow producing stocks we're observing.
BIO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 45.83% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Bio-Rad Laboratories Inc? See MD, BAX, GILD, HAPP, and JNJ.
Coherent Market Insights released a new market study on 2020-2027 Cancer Biomarkers Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence.
Global Liquid Biopsy Market research report provides an in-depth analysis of the industry and economy-wide database for the business management that could potentially offer development and profitability for players in this market. The Liquid Biopsy Market report discusses all major
DUBLIN--(BUSINESS WIRE)--The "Bacterial and Plasmid Vectors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Major players in the bacterial and plasmid vectors market are Sigma-Aldrich Inc., ATUM, QIAGEN, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories and New England Biolabs. The global bacterial and plasmid vectors market is expected to decli